Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: EXCRETION Clear all
Recruiting Phase 2 Interventional

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

NCT06059118
View directory record Official record
Conditions
Prostate Cancer
Interventions
DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 21, 2026, 7:46 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel

NCT00868361
View directory record Official record
Conditions
Healthy
Interventions
Talampanel (non-radiolabeled), [14C] Talampanel
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 16, 2009 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People

NCT05580003
View directory record Official record
Conditions
Healthy
Interventions
PF-07817883, Placebo, Midazolam, Moxifloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Distribution, Metabolism And Excretion Study For GSK221149A

NCT00457925
View directory record Official record
Conditions
Obstetric Labour, Premature, Premature Labor
Interventions
GSK221149A
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

NCT01663389
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 1000 mg containing radioactive 14C-GSK1322322, GSK1322322 1200 mg containing radioactive 14C-GSK1322322
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 21, 2026, 7:46 AM EDT
Withdrawn Not applicable Interventional

Viberect Penile Vibratory Stimulation to Enhance Recovery of Erectile Function and Urinary Continence Post-Prostatectomy

NCT01718704
View directory record Official record
Conditions
Erectile Dysfunction Following Radical Prostatectomy, Urinary Incontinence of Non-organic Origin
Interventions
Viberect device
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 70 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects

NCT05817890
View directory record Official record
Conditions
Healthy
Interventions
Fadraciclib
Drug
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Herniorrhaphy Study for Opioid Elimination

NCT03695367
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011, Luer lock applicator, Vial access device, Ibuprofen, Acetaminophen, Ketorolac
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Anaheim, California • Pasadena, California • Draper, Utah + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 21, 2026, 7:46 AM EDT
Completed No phase listed Observational

Observational Registry Study of Quality of Life When Treating BTcP With Abstral

NCT01936636
View directory record Official record
Conditions
Quality of Life, Breakthrough Cancer Pain
Interventions
Fentanyl
Drug
Lead sponsor
Galena Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
36
States / cities
Mobile, Alabama • Peoria, Arizona • Scottsdale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Food Matrix Effect on Flavanol Absorption, Metabolism and Excretion: Methylxanthines

NCT03526107
View directory record Official record
Conditions
Healthy
Interventions
CF Control, CF-Theobromine, CF-Caffeine
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 60 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

NCT04234672
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-831 Oral Tablet, [14C]TAK-831 IV Infusion, [14C]TAK-831 Oral Suspension
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Absorption, Metabolism and Excretion of Apigenin and Apigenin Glycosides

NCT03526081
View directory record Official record
Conditions
Healthy
Interventions
Chamomile Tea, Parsley based drink, Parsley Yogurt, Apigenin, Parsley-based drink (II)
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 60 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 21, 2026, 7:46 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of a Dietary Supplement Versus Placebo on Serum PFAS Levels in Male Firefighters

NCT07846371
View directory record Official record
Conditions
Environmental Exposure, PFAS Exposure
Interventions
Streptococcus salivarius 46-SL1, Placebo
Dietary Supplement
Lead sponsor
Cambiotics ApS
Industry
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 7:46 AM EDT
Completed No phase listed Observational

Urinary Kidney Injury Molecule-1 (KIM-1) Excretion As Biomarker for Injury in Kidney Transplant Recipients

NCT00805571
View directory record Official record
Conditions
Kidney Transplant Dysfunction
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
3 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2010 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Low and High Phytosterol Diets With Respect to Cholesterol Metabolism

NCT00860509
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Heart Disease
Interventions
Low Phytosterol and High Phytosterol Diets
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects

NCT04927793
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
EDP-938
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects

NCT05657834
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-TVB-2640
Drug
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Phase 1Phase 2 Interventional

CCR5-modified CD4+ T Cells for HIV Infection

NCT03666871
View directory record Official record
Conditions
HIV Infections
Interventions
SB-728-T, Expanded unmodified autologous CD4+ T cells
Biological
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.

NCT00426140
View directory record Official record
Conditions
Advanced Malignancies, Solid Tumors
Interventions
Patupilone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Not applicable Interventional

Methods for Effective Disposal of Surplus Analgesics to Facilitate Elimination

NCT05991687
View directory record Official record
Conditions
Surgery, Analgesics, Opioids
Interventions
In-home drug disposal pouch, Mail-in prepaid envelope
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Radiolabeled Study of CC-220 in Healthy Male Subjects

NCT03294603
View directory record Official record
Conditions
Healthy Volunteer
Interventions
CC-220, [14C]
Drug · Radiation
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants

NCT06227975
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-BMS-986368
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Oct 21, 2026, 7:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women

NCT00499928
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced Oct 21, 2026, 7:46 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)

NCT02044601
View directory record Official record
Conditions
Lung Cancer
Interventions
Onartuzumab, Erlotinib, Paclitaxel, Carboplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 21, 2026, 7:46 AM EDT